Shimonishi, Naruto http://orcid.org/0000-0002-0157-5215
Sasai, Kana
Ogiwara, Kenichi
Furukawa, Shoko
Nakajima, Yuto
Mizumachi, Kuniyoshi
Yada, Koji
Takeyama, Masahiro
Shima, Midori
Mizuno, Narumi
Nogami, Keiji
Article History
Received: 5 June 2023
Revised: 4 September 2023
Accepted: 12 September 2023
First Online: 6 October 2023
Declarations
:
: N. Shimonishi taught a course endowed by the CSL Behring. K. Sasai has no conflicts of interest to declare. K. Ogiwara received personal fees from Chugai Pharmaceutical Co. Ltd. taught a course endowed by CSL Behring. K. Yada taught a course endowed by the Shire Plc and Takeda Pharmaceutical Co., Ltd. S. Furukawa received personal fees from Chugai Pharmaceutical Co., Ltd., and taught a course endowed by CSL Behring. Y. Nakajima received a grant from Takeda Pharmaceutical Co. Ltd. K. Mizumachi has no conflict of interest to disclose. M. Takeyama received personal fees from Chugai Pharmaceutical Co., Ltd., KM Biologics Co., Bayer AG, and CSL Behring. M. Shima has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hofmann-La Roche Ltd.; personal fees and non-financial support from Sysmex Co.; grants from Takeda Pharmaceutical Co., Sanofi S. A., CSL Behring Co., KM Biologics Co., and Novo Nordisk A/S; personal fees from Bayer AG, Bioverativ Inc., and BioMarin Pharmaceutical Inc.; and is an inventor of the patents related to emicizumab. N. Mizuno is an employee of Chugai Pharmaceutical Co., Ltd. K. Nogami has received grants, personal fees, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hofmann-La Roche Ltd.; grants, personal fees, and non-financial support from Sysmex Co. and Sekisui Medical; grants and personal fees from Takeda Pharmaceutical Co.; grants and personal fees from Sanofi S.A; personal fees from CSL Behring Co.; grants and personal fees from KM Biologics Co.; grants and personal fees from Novo Nordisk A/S; grants and personal fees from Bayer AG; grants and personal fees from Bioverativ Inc.; and grants and personal fees from Shire Plc; personal fees from Fujimoto Seiyaku; and is an inventor of the patents related to emicizumab.